Fluorescent Leukocytes as a Marker of Early Sepsis/Severity (FLAMES)
NEUTROPHIL FLUORESCENCE AS AN EARLY BIOMARKER OF SEPSIS SEVERITY IN THE EMERGENCY DEPARTMENT
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Julie HELMS, Professor
- Phone Number: +33 3 69 55 13 69
- Email: julie.helms@chru-strasbourg.fr
Study Locations
-
-
-
Strasbourg, France, 67098
- The University Hospitals of Strasbourg, Intensive Care Medicine Department - New Civil Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥ 18 years
- Admission to the ED
- Suspected or proven infection defined by the prescription of antibiotic therapy within 24 hours following admission to the ED
- Collection of an EDTA blood sample as part of routine care
- Patient informed and has not expressed opposition
Exclusion Criteria:
- Pregnancy or breastfeeding
- Legal protection measure (guardianship, curatorship, judicial protection)
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Emergency Patients
Prospective multicenter observational cohort study evaluating the prognostic value of neutrophil fluorescence parameters measured at emergency department admission using a novel hematology analyzer.
Data are collected from routine blood samples and used to develop an artificial intelligence model without additional intervention.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluate the association between neutrophil fluorescence, whether isolated or integrated into an AI model based on CBC results combined with the advanced multiparametric capabilities of the SthemA 801 analyzer
Time Frame: 3 days
|
The primary evaluation criterion is the occurrence of sepsis or septic shock within 72 hours following admission to the Emergency Department, defined according to SEPSIS-3 by at least one of the following:
|
3 days
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Systemic Inflammatory Response Syndrome
- Inflammation
- Hematologic Diseases
- Blood Coagulation Disorders
- Hemorrhagic Disorders
- Shock
- Thrombophilia
- Pathological Conditions, Signs and Symptoms
- Hemic and Lymphatic Diseases
- Sepsis
- Shock, Septic
- Disseminated Intravascular Coagulation
Other Study ID Numbers
Other Study ID Numbers
- RC26_0024
- CE-2026-37 (Other Identifier: ETHICS COMMITTEE of the Faculties of Medicine, Dentistry, Pharmacy, Nursing Schools, Physiotherapy, Midwifery, and Hosp)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.